Search

Displaying results 1971 - 1980 of 2954 in total
  1. Drug

    Lucanthone

    go.drugbank.com/drugs/DB04967
    Investigational

    (From Martindale The Extrapharmacopoeia, 30th ed., p46). It is currently being tested as a radiation sensitizer.

  2. Drug

    NP-50301

    go.drugbank.com/drugs/DB05662
    Experimental

    It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S.

  3. Drug

    Ruxolitinib

    go.drugbank.com/drugs/DB08877
    ApprovedInvestigational

    [A229938] Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. … [A229708] Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed.

  4. Drug

    LSZ-102

    go.drugbank.com/drugs/DB15362
    Investigational

    LSZ-102 is under investigation in clinical trial NCT02734615 (Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers).

  5. Drug

    FM-VP4

    go.drugbank.com/drugs/DB05449
    Investigational

    FM-VP4, is a novel hydrophilic phytostanol analogue representing a new class in cholesterol-lowering drugs called cholesterol absorption inhibitors. FM-VP4 has been shown to inhibit cholesterol absorption and to lower plasma LDL-choleste...

  6. Drug

    Testosterone cypionate

    go.drugbank.com/drugs/DB13943
    ApprovedInvestigational

    It was developed by the company Pharmacia and Upjohn and FDA approved on July 25, 1979.

  7. Drug

    Delgocitinib

    go.drugbank.com/drugs/DB16133
    ApprovedInvestigational

    [A264703] On July 23, 2025, delgocitinib was also granted approval by the FDA.[L53508]

  8. Drug

    Aficamten

    go.drugbank.com/drugs/DB18490
    ApprovedInvestigational

    [L54788] Approved by the FDA on December 19, 2025, aficamten is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and

  9. Drug

    2,4-Dinitrophenol

    go.drugbank.com/drugs/DB04528
    Experimental

    (Stedman, 26th ed)

  10. Drug

    TBX-3400

    go.drugbank.com/drugs/DB17370
    Investigational

    TBX-3400 is an investigational cell-based immunotherapy consisting of autologous peripheral blood mononuclear cells (PBMCs) treated ex vivo with TBX-4000, which is a recombinant TAT-MYC fusion protein.